multiple indications (Crohn's disease, ulcerative colitis, hidradenitis suppurativa, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis)
Rheumatology · 2020–2020
1decision
1medicine
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| adalimumab Extension of listing for adalimumab biosimilar (Hadlima) to additional indications for which the reference product Humira is PBS-listed: severe Crohn disease,… | Jul 2020 | Recommended | none received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.